Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Sells $53,840.83 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman sold 4,483 shares of the business’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $12.01, for a total transaction of $53,840.83. Following the sale, the chief financial officer now owns 159,626 shares of the company’s stock, valued at approximately $1,917,108.26. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Robert Thomas Freeman also recently made the following trade(s):

• On Thursday, October 31st, Robert Thomas Freeman sold 36,197 shares of Alignment Healthcare stock. The shares were sold at an average price of $12.04, for a total transaction of $435,811.88.
• On Monday, October 14th, Robert Thomas Freeman sold 30,500 shares of Alignment Healthcare stock. The shares were sold at an average price of $11.50, for a total transaction of $350,750.00.
• On Tuesday, October 8th, Robert Thomas Freeman sold 39,320 shares of Alignment Healthcare stock. The shares were sold at an average price of $12.04, for a total transaction of $473,412.80.
• On Tuesday, October 1st, Robert Thomas Freeman sold 21,375 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.66, for a total value of $227,857.50.
• On Friday, September 13th, Robert Thomas Freeman sold 14,500 shares of Alignment Healthcare stock. The stock was sold at an average price of $12.00, for a total value of $174,000.00.
• On Wednesday, September 11th, Robert Thomas Freeman sold 8,561 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.01, for a total value of $85,695.61.
• On Wednesday, September 4th, Robert Thomas Freeman sold 1,650 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.00, for a total value of $16,500.00.

Alignment Healthcare Trading Up 5.7 %

Shares of NASDAQ:ALHC traded up $0.67 during trading on Thursday, reaching $12.40. The company’s stock had a trading volume of 2,410,721 shares, compared to its average volume of 1,029,118. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $2.37 billion, a PE ratio of -15.12 and a beta of 1.47. Alignment Healthcare, Inc. has a 12 month low of $4.46 and a 12 month high of $12.44. The firm’s 50 day simple moving average is $10.67 and its two-hundred day simple moving average is $8.71.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). The business had revenue of $692.43 million during the quarter, compared to the consensus estimate of $662.11 million. Alignment Healthcare had a negative net margin of 6.85% and a negative return on equity of 101.10%. The firm’s quarterly revenue was up 51.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.19) earnings per share. On average, research analysts predict that Alignment Healthcare, Inc. will post -0.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ALHC. TD Cowen upped their price objective on Alignment Healthcare from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Tuesday, August 6th. Barclays increased their price target on Alignment Healthcare from $7.00 to $8.00 and gave the stock an “underweight” rating in a research note on Wednesday. Robert W. Baird increased their price target on Alignment Healthcare from $10.00 to $11.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 14th. KeyCorp started coverage on Alignment Healthcare in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Finally, UBS Group increased their price target on Alignment Healthcare from $9.00 to $12.00 and gave the stock a “neutral” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.33.

Hedge Funds Weigh In On Alignment Healthcare

A number of institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. increased its position in shares of Alignment Healthcare by 1,335.1% during the third quarter. Principal Financial Group Inc. now owns 194,043 shares of the company’s stock worth $2,294,000 after acquiring an additional 180,522 shares during the period. nVerses Capital LLC purchased a new position in Alignment Healthcare during the third quarter valued at approximately $95,000. Creative Planning increased its holdings in Alignment Healthcare by 20.0% during the third quarter. Creative Planning now owns 12,442 shares of the company’s stock valued at $147,000 after buying an additional 2,072 shares during the period. SG Americas Securities LLC purchased a new position in Alignment Healthcare during the third quarter valued at approximately $521,000. Finally, Mackenzie Financial Corp increased its holdings in Alignment Healthcare by 110.0% during the second quarter. Mackenzie Financial Corp now owns 36,526 shares of the company’s stock valued at $286,000 after buying an additional 19,129 shares during the period. 86.19% of the stock is owned by hedge funds and other institutional investors.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.